Skip to main content
About Us > Prof. Isabella Orienti

Prof. Isabella Orienti


Prof. Isabella Orienti Curriculum vitae


2005-2016          Full Professor of Pharmaceutical Technology in the University of Bologna-Alma Mater Studiorum (Italy) Department of Pharmacy and Biotechnology

2001                     Qualification as a Full Professor in the Faculty of Pharmacy, University of Bologna

1991                     Associated Professor in the Department of Pharmaceutical Sciences, Faculty of Pharmacy, University of Bologna, Pharmaceutical-Technological-Disciplinary Area.

1990                     Researcher in the Department of Pharmaceutical Sciences, Faculty of Pharmacy, University of Bologna.

1984                     University Degree in Chemistry and Pharmaceutical Technology at the University of Bologna


Teaching Activity: Pharmaceutical Technology, Biotechnology of Drug Targeting and Release, Applied Pharmaceutical Technology of Nanoencapsulation.

Scientific Activity and Research Interests

Nanoencapsulation of antitumor drugs as a strategy to increase their therapeutic efficacy. Development of amphiphilic macromolecules by partial substitution of oligo/polysaccharides or proteins with hydrophilic and lipophilic substituents to obtain self-assembling carriers for antitumor drug targeting. Preparation of ion-pair supramolecular aggregates as innovative Drug Delivery Systems. The recent scientific activity has focused in particular on nanoencapsulation of Fenretinide, the most studied retinoid in cancer research in the last decade, due to its antitumor efficacy on a wide range of tumors without significant side effects. Fenretinide, however, in spite of its favourable profile is characterized by low bioavailability that strongly limits its use in cancer therapy. Nanoencapsulation aims at enhancing Fenretinide bioavailability and target the drug to the tumor environment by modulation of the carrier physico-chemical properties and possible linkage of targeting moieties to the carrier surface. The scientific activity is documented by 52 publications and 5 Patents the most of which on Fenretinide in the last years. This make Prof. Isabella Orienti one of the main experts on drug nanoencapsulation worldwide.

International Collaborations

Division of Hematology/Oncology and Bone Marrow Transplantation at Nationwide Children’s Hospital. Center for Clinical and Translational Science and Training, 700 Childrens Dr, Columbus, OH USA

Northern Institute for Cancer Research, University of Newcastle upon Tyne, NE2 4HH, Newcastle upon Tyne, UK

National Collaborations

Istituto superiore di Sanita’ Department of Ematology and Oncology (Roma)

IRST Istituto Scientifico Romagnolo per lo studio e la cura dei tumori (Meldola FC)

INMI Istituto Nazionale per le Malattie Infettive L. Spallanzani (Roma)

Policlinico Universitario Gemelli Pediatric Oncology (Roma)



1) WO 2016/038534 A1 (2016) “Fenretinide Complexes” [Isabella Orienti; Ruggero De Maria Marchiano; Ann Pegna


2) WO 2015/103005 (2015) “Amphiphilic Amine Compounds and their use as therapeutic agents and nanocarriers”

[Cripe Timothy P., Currier Mark A., Orienti Isabella] (Nationwide Children’s Hospital OH USA)

3) WO2007IT00552 (2007): “Amphilic Dextrin Conjugates and their use in pharmaceutical formulataions as

complexing agents for hydrophobic drugs to improve the aqueous solubility and consequently the therapeutic efficacy

of the complexed drugs” [Istituto Giannina Gaslini; Isabella Orienti]

4) IT2002PD00196 (2002): “Polimeri autoassemblanti, processo per la loro preparazione e loro uso come sistemi di

veicolazione di farmaci insolubili in acqua” [Isabella Orienti]

5) IT1998MI00078 (1998): “Formulazione orale a rilascio protratto di acidi grassi polinsaturi, in particolare per il

rilascio di acidi omega 3 polinsaturi” [Andrea Belluzzi; Stefano Boschi; Isabella Orienti; Vittorio Zecchi]


Our Effort

Open Therapeutics is a major backer of open science and open access efforts.

Open Therapeutics freely provides to science, technology, engineering, and math (STEM) scientists, or another other seriously interested persons, intellectual properties (patents, etc.), grant funding, lab equipment, document development tools, and preprint server in a collaboration platform (Therapoid™).

When the researchers advance the intellectual properties, s/he gains ScienceCoins™; a blockchain-based cryptocurrency.